IL325331A - Tyk2 inhibitors, compositions containing them and their uses - Google Patents
Tyk2 inhibitors, compositions containing them and their usesInfo
- Publication number
- IL325331A IL325331A IL325331A IL32533125A IL325331A IL 325331 A IL325331 A IL 325331A IL 325331 A IL325331 A IL 325331A IL 32533125 A IL32533125 A IL 32533125A IL 325331 A IL325331 A IL 325331A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- tyk2 inhibitors
- tyk2
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2023/100508 WO2024254832A1 (fr) | 2023-06-15 | 2023-06-15 | Inhibiteurs de tyk2 et compositions et procédés associés |
| PCT/CN2024/099407 WO2024255886A1 (fr) | 2023-06-15 | 2024-06-14 | Inhibiteurs de tyk2, compositions et procédés associés |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325331A true IL325331A (en) | 2026-02-01 |
Family
ID=93851118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325331A IL325331A (en) | 2023-06-15 | 2025-12-14 | Tyk2 inhibitors, compositions containing them and their uses |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4727935A1 (fr) |
| JP (1) | JP2026521561A (fr) |
| KR (1) | KR20260049523A (fr) |
| CN (1) | CN121843931A (fr) |
| AU (1) | AU2024304652A1 (fr) |
| IL (1) | IL325331A (fr) |
| TW (1) | TW202502764A (fr) |
| WO (2) | WO2024254832A1 (fr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013047813A1 (fr) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | Dérivé de 1,2,4-triazine-6-carboxamide |
| WO2013117649A1 (fr) * | 2012-02-10 | 2013-08-15 | Galapagos Nv | Dérivés d'imidazo [4, 5-c] pyridine utiles pour le traitement de maladies dégénératives et inflammatoires |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| EP3181564B1 (fr) * | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Composés d'aminopyrimidine comme inhibiteurs de mutants egfr de t790m |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| TW202317561A (zh) * | 2021-07-01 | 2023-05-01 | 美商羅曼德生物治療公司 | 作為治療劑的具有1h—吡唑并[4,3—c]吡啶—6—胺基的化合物 |
| TW202339749A (zh) * | 2021-12-16 | 2023-10-16 | 大陸商凌科藥業有限公司 | Tyk2抑制劑及其組合物和方法 |
-
2023
- 2023-06-15 WO PCT/CN2023/100508 patent/WO2024254832A1/fr not_active Ceased
-
2024
- 2024-06-14 JP JP2025572759A patent/JP2026521561A/ja active Pending
- 2024-06-14 EP EP24822833.0A patent/EP4727935A1/fr active Pending
- 2024-06-14 CN CN202480052904.0A patent/CN121843931A/zh active Pending
- 2024-06-14 WO PCT/CN2024/099407 patent/WO2024255886A1/fr not_active Ceased
- 2024-06-14 TW TW113122074A patent/TW202502764A/zh unknown
- 2024-06-14 AU AU2024304652A patent/AU2024304652A1/en active Pending
- 2024-06-14 KR KR1020267001014A patent/KR20260049523A/ko active Pending
-
2025
- 2025-12-14 IL IL325331A patent/IL325331A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026521561A (ja) | 2026-06-30 |
| EP4727935A1 (fr) | 2026-04-22 |
| TW202502764A (zh) | 2025-01-16 |
| KR20260049523A (ko) | 2026-04-14 |
| CN121843931A (zh) | 2026-04-10 |
| AU2024304652A1 (en) | 2026-01-22 |
| WO2024255886A1 (fr) | 2024-12-19 |
| WO2024254832A1 (fr) | 2024-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4448514A4 (fr) | Inhibiteurs de tyk2 et compositions et procédés associés | |
| IL326350A (en) | Benzopyridinones and benzopyrimidinones as pi3k inhibitors | |
| IL318706A (en) | Compositions and methods for inducing proptosis | |
| IL315862A (en) | Angiotensinogen modulators and methods of using them | |
| IL319049A (en) | TYK2 inhibitors and their uses | |
| AU2024391389A1 (en) | Tyk2 inhibitors and uses thereof | |
| GB202316199D0 (en) | Compositions and methods and uses thereto | |
| GB202209588D0 (en) | Methods and compositions | |
| GB202217944D0 (en) | Compositions and method | |
| CA3295315A1 (fr) | Inhibiteurs de tyk2, compositions et procédés associés | |
| CA3295318A1 (fr) | Inhibiteurs de tyk2 et compositions et procédés associés | |
| GB2635318B (en) | Methods and compositions | |
| IL317852A (en) | 3-βHSD1 inhibitors and compositions and uses thereof | |
| IL321428A (en) | Compounds and methods | |
| GB202316109D0 (en) | Methods and compositions | |
| GB202311858D0 (en) | Methods and compositions | |
| GB202308901D0 (en) | Methods and compositions | |
| GB202211117D0 (en) | Compositions and methods for non-immunogenecity | |
| GB202305427D0 (en) | Methods and compositions | |
| GB202304240D0 (en) | Compositions and methods | |
| IL315882A (en) | Antibodies against ILT4, preparations and methods | |
| GB202219851D0 (en) | Compositions and methods | |
| GB202206268D0 (en) | Compositions and methods | |
| GB202205579D0 (en) | Methods and compositions | |
| GB202306393D0 (en) | Trna-based methods and related compositions |